SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually.
Related news for (SLS)
- Afternoon Watchlist Builds as Busy Biotech, Blockbuster IPs & Big Institutional Bets Power Late-Day Surge
- MoBot’s Stock Market Highlights – 08/13/25 12:00 PM
- Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
- 24/7 Market News Snapshot 13 August, 2025 – ReShape Lifesciences, Inc. Common Stock (NASDAQ:RSLS)
- ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System